Influenza B Infection Market Size, Share | Industry Growth, 2031Posted by pooja on September 1st, 2022 Influenza B infection is considered as one of the common conditions that affects a large number of people across the globe, caused due to the influenza virus B genera of the family. The condition of influenza B infection requires proper medications and treatments in order to avoid severe complications. Influenza is commonly classified as type A, B, or C, depending on the protein composition of the virus. Influenza B infection is caused by influenzavirus B genera of the family Orthomyxoviridae and is found only in humans. Common symptoms of the infection include runny nose, chills, fever, muscle pain, sore throat, fatigue, coughing, and general weakness. Nausea and vomiting is also observed in some cases, particularly in children. The global influenza B infections market can be segmented based on drug class, pipeline assessment and geography. Histopathological examinations help in assessing airway, and tissues of lung, heart, and lymph node for determining influenze B infection. Various molecules under pipeline for treating influenza B infections are BTL- TML001, favipiravir, and CR-9114. Some of the key players contributing to the global influenza B infections market have been AltraVax, Inc., Autoimmune Technologies, LLC, Crucell N.V., Chimerix, Inc., REPLICor, Inc., Humabs BioMed SA, ContraFect Corporation, and Takeda Pharmaceutical Company Limited. Get Sample Copy Of This Report: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=290 About TMR Research Contact: Like it? Share it!More by this author |